Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shannon Lubaczewski"'
Autor:
Stanley Cohen, Jean S. Beebe, Vishala Chindalore, Shunjie Guan, Mina Hassan-Zahraee, Madhurima Saxena, Li Xi, Craig Hyde, Sarita Koride, Robert Levin, Shannon Lubaczewski, Mikhail Salganik, Abigail Sloan, Erin Stevens, Elena Peeva, Michael S. Vincent, David A. Martin, Myron Chu
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-18 (2024)
Abstract Background The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5
Externí odkaz:
https://doaj.org/article/de4e6e08230342d8a8ccd262c81c4143
Autor:
Jeffrey Crawford, Shannon Lubaczewski, Anil Tarachandani, Magdalena A. Harrington, Yan Weng, Ruolun Qiu, Susie M. Collins, Michelle I. Rossulek, James H. Revkin
Publikováno v:
Cancer Research. 83:CT054-CT054
Background: Cancer cachexia is a multifactorial metabolic syndrome of wasting characterized by anorexia, unintended weight loss, and decreased skeletal muscle mass, leading to progressive functional impairment, fatigue, diminished quality of life, po
Autor:
Phillip B. Chappell, Sara Ramaker, Sharon B. Wigal, Shannon Lubaczewski, Donna Palumbo, Richat Abbas
Publikováno v:
J Child Adolesc Psychopharmacol
Objective: The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), classifies attention-deficit/hyperactivity disorder (ADHD) as a neurodevelopmental disorder, with symptoms becoming apparent as early as the preschool years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbfc124a37b54172be406b9d45e24734
https://europepmc.org/articles/PMC7047251/
https://europepmc.org/articles/PMC7047251/
Autor:
Robert L. Findling, Sarah Atkinson, Sara Ramaker, Richat Abbas, Dalia B. Wajsbrot, Shannon Lubaczewski, Richard D. England
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years)
Autor:
Alice I. Nichols, Shannon Lubaczewski, Kyle Matschke, Tanya Ramey, Yali Liang, Gabriel Braley
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 52:830-841
Background Potential drugdrug interactions are a concern for patients taking tamoxifen. Objective This study was designed to determine the effect of coadministering desvenlafaxine on tamoxifen pharmacokinetics. Materials and methods This open-label,
Publikováno v:
Professional Case Management. 19:63-74
Purpose The purpose of this study was to identify potential discordance between physician and patient rated measures of depression used by primary care physicians and psychiatrists. Primary practice setting This study collected data from primary care
Autor:
Gabriel Braley, Shannon Lubaczewski, Yali Liang, Tanya Ramey, Alice I. Nichols, Kyle Matschke
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Study background: The atypical antipsychotic aripiprazole is commonly coadministered with antidepressant drugs as an adjunctive treatment for depression. The goal of the current study was to assess the potential for multiple-dose treatment with the a
Autor:
Jeffrey Paul, Alice I. Nichols, Tanya Ramey, Joel A Posener, Gabriel Braley, Shannon Lubaczewski, Alain Patat, Jessica A Behrle, Kyle Matschke, Yali Liang
Publikováno v:
Journal of Bioequivalence & Bioavailability.
A series of 3 open-label, 2-period, sequential studies were conducted to assess the impact of desvenlafaxine on cytochrome P450 3A4 (CYP3A4) enzyme-mediated metabolism, and the effect of CYP3A4 inhibition on desvenlafaxine metabolism. Study 1 evaluat
Autor:
Boadie W. Dunlop, Christine J. Guico-Pabia, Sujana Reddy, Shannon Lubaczewski, Lingfeng Yang, Kristen Focht
Publikováno v:
Journal of clinical psychopharmacology. 31(5)
This is the first study to assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) for improving depressive symptoms and functioning exclusively in employed patients with major depressive disorder (MDD).Gainfully employed (